In schizophrenia and other psychiatry studies, enrollment is only half the challenge. High dropout rates can threaten timelines, increase costs, and introduce data variability that delays decision-making. At Worldwide Clinical Trials, we approach retention as a core component of study design, instead of implementing after problems arise. By combining therapeutic expertise, participant-centric protocols, and proactive site support, we’ve helped sponsors accelerate enrollment, improve retention, and build long-term development partnerships.
Read our fact sheet to learn more about our Retention by Design approach, including:
- Protocol optimization through cross-functional critique, enhancing signal detection and participant experience within an enriched population
- A recruitment plan that documents the patient treatment pathway, leverages awareness campaigns and community engagement, and optimizes site performance
- A retention-first strategy that helps sponsors reduce dropout risk, accelerate study execution, improve data quality, and create a stronger foundation for future development programs
- Proven results, including a psychiatry program that achieved approximately 3x faster enrollment and closed at +2.5% of the statistically determined goal of 350 participants
